Novel therapeutic agents combined with innovative modes of delivery and non-invasive imaging of drug delivery, pharmacokinetics and efficacy are crucial in developing effective clinical anticancer therapies. In this study, we have created and characterized multiple novel variants of anti-angiogenic protein thrombospondin (aaTSP-1) that comprises unique regions of three type-I-repeats of TSP-1 and used engineered human neural stem cells (hNSC) to provide sustained on-site delivery of secretable aaTSP-1 to tumor-vasculature. We show that hNSC-aaTSP-1 has anti-angiogenic effect on human brain and dermal microvascular endothelial cells co-cultured with established glioma cells and CD133 þ glioma-initiating cells. Using human glioma cells and hNSC engineered with different combinations of fluorescent and bioluminescent marker proteins and employing multi-modality imaging techniques, we show that aaTSP-1 targets the vascularcomponent of gliomas and a single administration of hNSC-aaTSP-1 markedly reduces tumor vessel-density that results in inhibition of tumor-progression and increased survival in mice bearing highly malignant human gliomas. We also show that therapeutic hNSC do not proliferate and remain in an un-differentiated state in the brains of glioma-bearing mice. This study provides a platform for accelerated development of future cell-based therapies for cancer.
Introduction
Human gliomas, in their proliferative stage, are highly vascularized tumors and their persistence and growth are dependent on the pathological formation of new capillary blood vessels. Angiogenesis inhibition could therefore be an efficient therapeutic strategy for treating malignant gliomas. However, the benefit of current antiangiogenic agents as stand alone therapies has been modest. The major limitations in the progress of antiangiogenic agents to the clinics have been their short circulating half-life, dose-limiting toxicity and the noninvasive methods to monitor anti-angiogenic therapies in vivo. This has prompted the (1) engineering of novel anti-angiogenic agents that can be delivered through innovative modes of delivery; and (2) integration of imaging agents into target cells, delivery vehicles and therapeutic molecules to visualize drug delivery, pharmacokinetics and therapeutic efficacy. Both efforts are aimed at developing effective anti-angiogenic therapies for gliomas.
In recent years, the anti-angiogenic potential of thrombospondin-1 (TSP-1) has been extensively examined. TSP-1 is a 420 kD glycoprotein consisting of a homotrimer containing a NH2-terminal domain, a procollagen domain, type 1, 2 and 3 repeats and a COOH-domain (Lawler and Detmar, 2004) . The antiangiogenic potential of TSP-1 is mainly driven by its three type 1 repeats (TSRs) and a number of studies have shown the anti-angiogenic and anti-tumor effect of TSRs and the peptides originating from TSRs (Bogdanov et al., 1999; Liu et al., 2003; Lawler and Detmar, 2004; Rusk et al., 2006; Anderson et al., 2007) . For instance, a therapeutic peptide, ABT-510, derived from the GVITRIR sequence in the second TSR of TSP-1, has been approved for clinical trial in different cancer types (Hoekstra et al., 2006; Markovic et al., 2007) . The short half-life of anti-angiogenic TSP-1 peptides and the inability to non-invasively monitor their pharmacokinetics and efficacy are limitations to the TSP-1-mediated anti-angiogenic therapy. We reasoned that one strategy to overcome these limitations would be to construct a secretable and in vivo imageable version of anti-angiogenic (aa) TSP-1, comprising the regions of 3TSRs where most of the peptides used in preclinical and clinical settings have originated from; and use neural stem cells (NSC) as on-site delivery vehicles to deliver anti-angiogenic protein thrombospondin (aaTSP-1). We and others have previously shown that both mouse and human NSC (hNSC) migrate toward the tumor site when implanted in the contralateral hemisphere or in the close vicinity of the gliomas (Aboody et al., 2000; Tang et al., 2003; Shah et al., 2005 Shah et al., , 2008 . This tropism of NSC for brain tumors can be used for delivering therapeutic molecules (Ehtesham et al., 2002; Shah et al., 2005 Shah et al., , 2008 . In this study, we have created and characterized multiple secretable variants of aaTSP-1 and engineered hNSC with aaTSP-1 to elucidate its anti-angiogenic effects in vitro and in vivo.
Non-invasive imaging offers a huge potential to facilitate the development of novel cancer therapies. We have previously used dual-bioluminescence imaging to follow the fate of NSC and tumors in vivo Shah et al., 2005) . However, visualization of multiple biological events in therapeutic tumor models, such as simultaneous monitoring of delivery agents, therapeutic protein secretion, angiogenesis and tumor burden in real time, has remained largely unexplored so far. In this study, we have also incorporated different combinations of fluorescent and bioluminescent markers into glioma cells and NSC and used real-time optical imaging to simultaneously follow tumor burden, hNSC fate, in situ aaTSP-1 secretion from hNSC and its effects on tumor-associated vasculature in a highly malignant human glioma model.
Results
To study the role of secreted anti-angiogenic TSP-1 on human endothelial cells in vitro and its effect on glioma angiogenesis and progression in mouse models of gliomas, we created different versions of secretable aaTSP-1 encoding the regions of 3TSRs of TSP-1 (a.a. 412-499). The aaTSP-1 plasmid constructs consisting of N-terminal human Flt3 signal sequence (Ss) or the entire extracellular domain of human Flt3 (HF) as well as their His 6 -and FLAG-tagged variants to quantify secretion of aaTSP-1 are diagrammed in Figure 1a . These constructs were packaged into lentivirus (LV) virions and used to transduce hNSC in culture. hNSC were efficiently transduced with aaTSP-1 LVs as revealed by green fluorescent protein (GFP) fluorescence (Figure 1b ) and by flow cytometry (Figure 1c ) and expressed aaTSP-1, as shown by dot blot analysis on culture medium (Figure 1d ). To quantify secreted aaTSP-1 in the culture medium, we developed an enzyme-linked immunosorbent assay-based on Ni 2 þ -coated wells and biotinylated anti-FLAG antibody. A higher concentration of SsaaTSP-1 (240 ng/ml per 10 6 cells) compared with human HF-aaTSP-1 (160 ng/ml per 10 6 cells) protein was secreted in the culture medium (Figure 1e ) of hNSC transduced with different versions of His 6 -and FLAGtagged aaTSP-1 LVs. Furthermore, hNSC continuously secreted aaTSP-1 over a 15-day period (Figure 1f ) and the expression of aaTSP-1 in hNSC did not alter their growth rate (Figure 1g) .
To study the anti-angiogenic effects of different variants of aaTSP-1 in vitro, we first measured endothelial cell branch point formation and tubule length, the two most widely used surrogates to estimate angiogenesis in vitro, on human microvascular endothelial cells (HMVECs) incubated with conditioned medium from transduced hNSC. HMVECs incubated with Ss-aaTSP-1 containing conditioned medium showed a significant reduction in the formation of branching points ( Figure 2a ) and also tubule length (Supplementary Figure 1A ), as compared with the HF-aaTSP-1 or control-conditioned medium 18 h after incubation. There was no influence of N-terminal His and Cterminal FLAG tags on the anti-angiogenic potential of aaTSP-1 (Figures 2a and b) . We then tested conditioned medium from hNSC-Ss-aaTSP1 on human brain microvascular endothelial cells (HBMVECs). hNSCSs-aaTSP1 significantly inhibited the formation of branching points in HBMVECs (Figure 2c ; Supplementary Figures 1B and C). Glioma cells have been reported to secrete factors that promote angiogenesis (Hanahan and Weinberg, 2000; Papetti and Herman, 2002) . To study the potency of aaTSP1 on endothelial cells in presence of glioma cells, we performed additional co-culture experiments of HMVECs and HBMVECs with either established human glioma cells expressing DsRed2 (Gli36-EGFRvIII-DsRed2) or CD133 positive and negative primary human glioma cells. The conditioned medium from hNSC-Ss-aaTSP-1 caused a reduction in branching points in both HMVECs ( Figure 2d ) and HBMVECs (Figure 2e ). HMVECs cocultured with either CD133 þ or CD133-primary glioma cells, and incubated in conditioned medium from hNSC-Ss-aaTSP-1 showed a significant reduction in average branching points (Figure 2f) . Finally, similar studies performed with a known VEGFR2 kinase inhibitor (cell permeable indolin-2-one class of RTK), showed an hNSC-Ss-aaTSP-1 comparable effect on HMVECs (Figure 2g ). These results reveal that NSCsecreted aaTSP-1 has anti-angiogenic effect on both HMVECs and HBMVECs in vitro and its efficacy is optimized by fusing it to the N-terminal human Flt3 Ss rather than to the entire extracellular domain of human Flt3. Furthermore, Ss-aaTSP-1 results in the considerable reduction in the angiogenic potential of endothelial cells when co-cultured with glioma cells and this effect is comparable to the known anti-angiogenic inhibitor used in pre-clinical settings.
To follow the secretion of Ss-aaTSP-1 (from here on named aaTSP-1) in vitro and in vivo, we created a C-terminal Gaussia luciferase (Gluc) fusion of aaTSP-1 (Figure 3a) . Branch point formation assays on HMVECs and HBMEVCs revealed that aaTSP-1-Gluc had considerably reduced potency as compared with aa-TSP-1 (data not shown). Gluc bioluminescence imaging on hNSC transduced with LV-aaTSP1-Gluc (Figure 3b) showed that hNSC-secreted aaTSP-1-Gluc in the culture medium (Figure 3c ). To simultaneously follow the fate In vivo imaging of stem cell-based anti-angiogenic therapy M van Eekelen et al of hNSC and secretion of aaTSP-1, hNSC were cotransduced with LV-aaTSP-1-Gluc and LV-GFP-Fluc and both hNSC and culture medium were imaged using two different substrates, coelenterazine and D-luciferin, respectively. Linear correlations between (1) aaTSP1-Gluc activity and culture medium volume; and (2) Fluc activity and the number of hNSC-secreting aaTSP-1 were shown by dual-in vitro bioluminescence imaging ( Figure 3d ). When a mix of glioma cells and hNSC coexpressing GFP-Fluc and aaTSP-1-Gluc was implanted subcutaneously in mice, dual-bioluminescence imaging showed that aaTSP-1 expression could be measured In vivo imaging of stem cell-based anti-angiogenic therapy M van Eekelen et al in vivo and that the expression of aaTSP-1 in vivo was stable over time ( Figure 3e ). To simultaneously follow tumor volumes, secretion of aaTSP-1 and localization of tumor cells and hNSC at a cellular resolution, we implanted hNSC-aaTSP-1-Gluc cells into mice with established Gli36-EGFRvIII-FD tumors, 2 mm from the site of implantation, in subcutaneous window chambers. Dual-bioluminescence imaging revealed that the tumor volumes (Figures 3f and h ) and aaTSP-1 secretion (Figures 3g and h ) could be sequentially detected, and subsequent intravital microscopy on the same mice revealed the homing of NSC-secreting aaTSP-1-Gluc to tumor cells (Figures 3i-n) at a cellular resolution in real time. These results reveal that the tumor volumes, antiangiogenic agents and the delivery vehicles can be monitored longitudinally in real-time in vivo and further show that aaTSP-1 secretion from NSC is stable in vivo and engineered hNSC home to tumors.
To assess the effects of aaTSP-1 delivered through engineered hNSC on gliomas in vivo, we first implanted a mix of human Gli36-EGFRvIII-FD glioma cells and either aaTSP-1 expressing or control GFP-Rluc-expressing hNSC. The presence of hNSC (green) within the implanted tumors (red) was confirmed by intravital microscopy 4 days after implantation (Figure 4a ). Serial Fluc bioluminescence imaging on mice revealed a significant reduction in glioma burden in mice bearing hNSC-expressing aaTSP-1 as compared with the hNSCexpressing control GFP-Rluc, starting at day 6 after implantation ( Figure 4a ). Histopathological analysis with anti-CD31 antibody on tumor sections revealed that control tumors presented significantly higher number of vascular endothelial cells than treated tumors (Figures 4b-d) . To simultaneously follow tumor cells, NSC and tumor vasculature at a cellular resolution, we created a human malignant glioma cell line expressing a new red shifted marker, tdTomato, which is the brightest of the red shifted fluorophore variants (Gli36-EGFRvIII-tdTomato) (Figure 4e ) (1.6 times brighter than DsRed2; t 0.5 for maturation: 1 h as compared with 7 h for DsRed2) and implanted a mix of therapeutic hNSC-aaTSP-1 or control hNSC-GFP-Rluc and Gli36-EGFRvIII-tdTomato tumor cells in subcutaneous window chambers. Intravital confocal microscopy on mice 4 days after implantation revealed that tumor cells, hNSC and vasculature could be detected simultaneously (Figures 4f -m) in both aaTSP-1 treated and control GFPRluc-treated mice. Furthermore, a significant reduction in the microvascular density within the tumor mass was observed in aaTSP-1-treated tumors (Figures 4j-n) as compared with the controls at day 6 after implantation ( Figures 4f-i and n) . These experiments show that anti-angiogenic effects of aaTSP-1 have a substantial influence on the growth and progression of tumor cells in subcutaneous glioma tumors. Furthermore, using different combinations of optical imaging modalities, anti-angiogenic effects of hNSC delivered aaTSP-1 can be monitored in real-time in vivo.
Next, we tested the effect of hNSC-aaTSP-1 in the intracranial glioma models. Two different sets of experiments were performed. In the first set of experiments, we implanted a mix of hNSC-aaTSP-1 or control hNSC-GFP-Rluc and Gli36-EGFRvIII-tdtomato tumor cells in a cranial window model. Similar to the subcutaneous window chamber model, intravital confocal microscopy on mice revealed that tumor cells, hNSC and blood vasculature could be detected simultaneously in both control GFP-Rluc (Figures 5a-d) and aaTSP-1 treated (Figures 5e-h ) mice. A considerable reduction in glioma volumes in tumors implanted with hNSC-aaTSP-1 (Figure 5a ) as compared with the controls (Figure 5e ) was observed 4 days after implantation. Furthermore, a significant reduction in vasculature around Gli36-EGFR-vIII-tdTomato/NSCaaTSP-1 transplanted areas was observed as compared with the controls (Figure 5i) .
A number of previous studies have revealed that repeated systemic administration of anti-angiogenic drugs in animal models result in controlled cell proliferation but incomplete eradication of established gliomas. In the second set of experiments, we assessed the effect of stem cell delivered aaTSP-1 on established gliomas by implanting hNSC-aaTSP-1 in the close vicinity of Gli36-EGFR-vIII-FD established gliomas. Dual-bioluminescence imaging revealed the progression of glioma tumors (Figure 5j ) and fate of hNSC in real time (Figure 5k ). Glioma growth was significantly reduced at day 6, 12 and 16 after implantation compared with the control hNSC-GFP-Rluc implanted animals, in which tumors grew more rapidly (Figure 5j ). KaplanMeier survival analysis revealed a statistically significant prolongation of the survival in the hNSC-aaTSP-1-treated group as compared with control hNSC-GFPRluc (Figure 5l ). Histological examination revealed prominent presence of endothelial cells in control tumors as compared with the aaTSP-1 tumors (Figures  5m-o) . These results show that a single administration of hNSC-aaTSP-1 in mice with established glioma result in significant reduction of tumor growth and prolonged survival.
To investigate the fate of transplanted hNSC-aaTSP-1 in mice, immunohistochemical analysis on brain sections from mice-bearing gliomas and implanted with hNSCaaTSP-1 was performed. A robust expression of NSC marker, nestin in hNSC 12 days after implantation was observed (Figures 6a-d) . Furthermore, a majority of hNSC-aaTSP-1 did not stain for the proliferation marker Ki67 (Figures 6e-h) , the astrocytic marker, GFAP (Figures 6i-l) and the neuronal marker, mitogenactivated protein-2 (Figures 6m-p) . However tumor cells were stained for Ki67 (Figures 6e-h ) and normal mouse brain stained for both GFAP (Figures 6i-l) and mitogen-activated protein-2 (Figures 6m-p) . These results reveal that therapeutic hNSC do not proliferate and remain in an un-differentiated state in the brains of glioma-bearing mice brains.
Discussion
In this study, we have engineered and characterized a secretable form of anti-angiogenic TSP-1. We show that
In vivo imaging of stem cell-based anti-angiogenic therapy M van Eekelen et al engineered hNSC-expressing secretable aaTSP-1 have a significant anti-angiogenic effect on different endothelial cell types co-cultured with both established and primary glioma cells. Using various fluorescent and bioluminescent proteins in combination with different optical imaging techniques, we show that hNSC-aaTSP-1 targets the vascular-component of gliomas. Furthermore, a single administration of NSC-aaTSP-1 markedly reduces tumor vessel-density resulting in inhibition of tumorprogression and increased survival in mice.
Human glioblastomas are richly vascularized tumors (Zagzag et al., 2000) that actively release a substantial amount of stimulating factors and promote angiogenesis either by direct interaction with endothelial cells or by secretion of a large number of factors (Guerin and Laterra, 1997) . In our co-culture experiments, the secreted aaTSP-1 was able to overcome the support of co-cultured glioma cells on endothelial cells, which use complex mechanisms to promote angiogenesis in their vicinity (Bergers and Benjamin, 2003; Jain et al., 2007) . It has been shown that CD133 þ brain tumor initiating cells interact physically with endothelial cells in culture, promote microvascular angiogenesis and are maintained in an undifferentiated state because of secreted factors from endothelial cells from their 'vascular niche' (Calabrese et al., 2007) . In this study, we show that the presence of secreted aaTSP-1 in the medium of human brain endothelial cells in co-culture with both isolated CD133 þ and CD133-cells from a resected human primary brain tumor have a similar effect. These results reveal that glioma cells, irrespective of having cancer stem cell-like properties, show similar sensitivity to the anti-angiogenic effect of aaTSP-1. These results confirm that aaTSP-1 is a potent inhibitor of endothelial In vivo imaging of stem cell-based anti-angiogenic therapy M van Eekelen et al cell migration and tubule formation induced by angiogenesis promoting factors secreted by tumor cells and present in the Matrigel basement membrane matrix. Sustained levels of angiogenic inhibitors including 3TSR are a potential key to improving the efficiency and potency of anti-angiogenic cancer therapy (Drixler et al., 2000; Kisker et al., 2001; Capillo et al., 2003; Batchelor et al., 2007) . The ability of the TSP-1 TSRs to target endothelial cells makes it an attractive candidate for anti-angiogenic therapy in cancer treatment. However, the short blood circulating half-life of 3TSR (Hanahan and Weinberg, 2000) is a limitation to maintaining stable systemic levels of aaTSP-1. Recent studies have shown that in vivo continuous administration of the 3TSRs through mini-osmotic pump improves the potency of antiangiogenic therapy in an orthotopic human cancer model compared with repeated bolus administration . In addition, the results of a phase I clinical trial of ABT-510, a peptide derived from TSRs (Hoekstra et al., 2006) , have further emphasized the need for continuous administration of peptides for anti-angiogenic therapy. In this study, we In vivo imaging of stem cell-based anti-angiogenic therapy M van Eekelen et al have engineered lentiviral vectors, which allow stable integration of transgenes into the host genome (Naldini et al., 1996) , to express a smaller region of TSR, comprising the whole of second TSR and parts of the first and the third TSR fused to the N-terminal hFLt3 Ss. Using the tumor-homing properties of hNSC Shah et al., 2005; Corsten and Shah, 2008) , our studies show a sustained and continuous hNSCmediated delivery of aaTSP-1 for at least 2 weeks after implantation of hNSC.
Our in vivo results show that hNSC-secreting aaTSP-1 within the tumors resulted in a significant reduction in tumor microvascular density. Secreted aaTSP-1 also exerted powerful anti-growth effects on non-established tumors in the subcutaneously implanted model. This is most likely because of the continuous secretion of aaTSP-1 by hNSC in close proximity to the tumor cells, which ensure effective local concentration of the antiangiogenic protein in vivo. Later experiments, using established glioma xenograft implanted intracranially followed by injection of aaTSP-1-expressing hNSC, also showed reduction of tumor size and microvessel density up to day 16 after hNSC implantation. This is in line with other studies that have revealed that anti-angiogenic therapies in animal models of glioma do not result in complete eradication of established gliomas but provide evidence of controlled cell proliferation (Tuettenberg et al., 2006) . Recent studies have shown that the use of anti-angiogenic drugs in human brain tumor patients normalizes the abnormal structure and function of the blood vessels, rendering them more efficient for the delivery of other therapeutic agents Duda et al., 2007; Jain et al., 2007) . On the basis of these studies, NSC expressing both aaTSP-1 and tumor-specific cytotoxic agents, such as S-TRAIL (Shah et al., 2004 (Shah et al., , 2005 Sasportas et al., 2009) can be engineered and the efficacy of this stem cell-based combination therapy can be tested in preclinical trials. The onsite delivery of therapeutic agents through stem cells to target both brain tumor cells and tumor-associated endothelial cells should allow for higher treatment efficiency and possibly for eradication of established gliomas.
The limited availability of noninvasive methods to monitor multiple molecular events has been one of the main limitations in testing the efficacy of various tumor therapy paradigms. In our previous studies, we have shown that we can follow delivery of viruses , NSCs (Shah et al., 2005) and quantify glioma burden in vivo (Shah et al., , 2005 Kock et al., 2007) using non-invasive bioluminescence imaging. In spite of the advantages and convenience of bioluminescence imaging for monitoring tumor growth, there are some disadvantages that should be taken into account while In vivo imaging of stem cell-based anti-angiogenic therapy M van Eekelen et al assessing fate of tumors and stem cells in vivo. The light transmission is attenuated by tissue, therefore deeper the luciferase-expressing cells within the body or intracranial tumors, the greater the signal attenuation. In our studies on fate of NSCs in intracranial gliomas described in Figure 5 , we show that as the tumor size (Fluc activity) increases, there is a considerable decreases in NSCs (Rluc activity) over 2 weeks. As the decrease is observed only at the BLI level and not in tissue sections described in Figure 6 , we believe that as the tumors grow, they shield NSC that then become almost undetectable by bioluminescence imaging by week 2. In addition, while bioluminescence imaging is an efficient method for longitudinal comparison, it does not offer high spatial resolution in vivo. However, combining bioluminescence imaging and confocal intravital microscopy offers great potential to image multiple events in real time. In this study, we have labeled tumor cells and stem cells with bimodal imaging markers (bioluminescent and fluorescent) expressed as a single transcript, which allows for expanding the number of events that can be visualized in real-time in vivo. To follow pharmacokinetics of therapeutic aaTSP-1 both in culture and in mouse models of glioma, we have also used a C-terminal fusion of aaTSP-1 with Gluc, which is a relatively new bioluminescent protein that has been proven to optimized brightness and stability over other luciferases (Verhaegent and Christopoulos, 2002) . Although Gluc fusion reduced the anti-angiogenic activity of aaTSP-1, it was shown to be an efficient tool for real-time quantification of secreted aaTSP-1 in vivo.
In addition, we have also used a blood pool agent, angiosense-750, to visualize the vasculature in the tumor area and the microvascular density within the tumors in dorsal skin fold and intracranial window preparations, which have been previously shown to facilitate the real-time analysis of angiogenesis and microcirculation in the tumors (Gondi et al., 2004) . Previous intravital microscopy data indicated that the blood half-life of angiosense-750 is more than 5 h, with essentially no extravasation into tumors during the first 30 min after intravenous administration (Montet et al., 2007) .
In conclusion, this study simultaneously sheds light on the pharmacokinetics of a novel variant of TSP-1, fate of engineered stem cells, tumor volumes and microvascular density and has implications in developing novel stem cell-based therapies for cancer.
Materials and methods
Generation of TSP-1 lentiviral vectors Lentiviral vectors, pLV CSC-IG bearing an internal ribosomal entry site-GFP element, were used as a backbone. The detailed construction of the therapeutic and diagnostic lentiviral vectors in this study is described in the Supplementary methods section.
Cell lines and cell culture Human Gli36 and Gli36-EGFRvIII and Gli36-EGFRvIII line-expressing Fluc-DsRed2 (Gli36-EGFRvIII-FD) human glioma cells and 293T/17 cells were grown as described earlier (Shah et al., 2005) . hNSC (kindly provided by Dr Alberto Martinez Serrano, University of Madrid, Spain) were grown as described earlier . HMVECs and HBMVECs (Cambrex, East Rutherford, NJ, USA) were grown as described in the Supplementary methods section. Primary human CD133 positive and negative glioma cells were kindly provided by Hiroaki Wakimoto (MGH, Boston, MA, USA).
Lentiviral transductions and stable cell lines hNSC were transduced with LV bearing different variants of aaTSP-1 or control LV-bearing GFP-Fluc or GFP-Rluc at multiplicity of infection ¼ 2 in a growth medium containing 4 mg/ml protamine sulfate (Sigma, St louis, MO, USA) and cells were visualized for GFP expression by fluorescence microscopy. Similarly, Gli36-EGFRvIII glioma cells were transduced with LV-tdTomato at multiplicity of infection ¼ 2 and visualized for tdTomato expression. Following expansion in culture, both hNSC and glioma cells were sorted by fluorescence-activated cell sorting (FACSAria Cell-Sorting System, BD Biosciences, San Jose, CA, USA). Two week postsort, cells were analyzed by flow cytometry (FACScalibur, BD Biosciences).
Western blot and dot blot analysis and enzyme-linked immunosorbent assays
The details on western blot analysis on cell lysates and dot blot analysis and enzyme-linked immunosorbent assay on conditioned culture medium is described in detail in the Supplementary methods section.
Matrigel assay
HMVECs and HBMEVCs were grown as described above. Eighty percent confluent 10-cm dishes of transduced hNSC were washed with phosphate-buffered saline and incubated in 10 ml hNSC growth medium for 24 h. Conditioned media was collected and centrifuged at 1000 revolutions per minute. Endothelial cells were plated on Matrigel (Chemicon, Temecula, CA, USA) and 24 h later LV-transduced hNSC-conditioned medium was added to Matrigel. Eighteen or 24 h later, photomicrographs were taken using the Nikon E400 light microscope (Nikon Instruments Inc., Melville, NY, USA). Endothelial cell branch points and tubule length was assessed and averaged on each of the photomicrograph (n ¼ 6). Coculture experiments were performed by simultaneously plating HMVECs and glioma cells on 20 ml of Matrigel in 96-well plates and 18 h later incubating cells with NSC-conditioned medium, followed by imaging on the next day. HMVECs cocultured with Gli36vIII-DsRed2 were incubated in a medium containing different concentrations (0.1-1 mM) of VEGFR2 kinase inhibitor 1 (Z)-3-[(2,4-dimethyl-3-(ethoxy carbonyl)-pyrrol-5-yl)methylidenyl]indolin-2-1 (EMD Chemicals, Gibbstown, NJ, USA) and 18 h later branch-points were measured as described above.
Pharmacokinetic assays
The in vitro dual-bioluminescence assays are described in the Supplementary methods section. For in vivo pharmacokinetics, SCID mice (SCID; 3 weeks of age; Charles River Laboratories, Wilmington, MA, USA) were anesthetized by isofluorine inhalation. Two different sets of experiments were performed: (1) hNSC-expressing aaTSP-1-Gluc and GFP-Fluc and Gli36-EGFRvIII cells were harvested by trypsinization. A mix of 3 Â 10 6 hNSC-aaTSP-1-Gluc/GFP-Fluc and 3 Â 10 6 Gli36-EGFR-vIII were implanted subcutaneously in SCID mice (n ¼ 4). Dual-bioluminescence imaging in vivo was performed
In vivo imaging of stem cell-based anti-angiogenic therapy M van Eekelen et al as described earlier (Sasportas et al., 2009) ; (2) Gli36-EGFRvIII-FD glioma cells (3 Â 10 6 ) were placed in the upper tissue layer of the center of the dorsal skin fold-window that were created as described earlier (Asaishi et al., 1981; Carmeliet and Jain, 2000) (n ¼ 6) and 4 days later, hNSCexpressing aaTSP-1-Gluc (1 Â 10 6 ) were placed around the tumor cells. Mice were sequentially imaged for dual-luciferase imaging as described earlier (Sasportas et al., 2009) . Intravital fluorescence microscopy was performed as described in the Supplementary methods section.
Tumor progression bioluminescence imaging in vivo Gli36-EGFRvIII-FD and hNSCs expressing aaTSP-1 or GFPRluc were harvested at 80% confluency and a mix of glioma cells (5 Â 10 6 ) and transduced hNSC (2.5 Â 10 6 ) (n ¼ 4 mice in each case; two implantations per mouse) was injected subcutaneously in isofluorine anesthetized SCID mice. To follow the progression of glioma cells in a subcutaneous tumor model, mice were imaged for Fluc activity on day 1, 6, 10 and 14 as described earlier (Sasportas et al., 2009 ). On day 15, mice were killed and the subcutaneous tumors were resurrected for histopathological analysis. For intravital microscopy in subcutaneous tumor models, dorsal skin fold-window was created as described above. A mix of Gli36-vIII-tdtomato glioma cells (1 Â 10 6 ) and hNSC-aaTSP-1 or hNSC-GFP-Rluc (1 Â 10 6 ) (n ¼ 6 in each case) were placed on the upper tissue layer in the center of skin window. Four days after implantation, mice were injected with Angiosense-750 (Visen Medical, Woburn, MA, USA; 20 nmol per mouse) intravenously and intravital microscopy was performed as described in the Supplementary methods section. Quantitative vascular analysis was performed by determination of micro vascular density, which was defined as the intensity of all newly formed microvessels in five randomized areas within the tumors.
To follow the effect of hNSC-secreting TSP-1 on growth of established gliomas in the brain, Gli36-EGFRvIII-FD glioma cells were harvested by trypsinization and implanted into right frontal lobe of SCID mice brains (80 000 cells per mouse, in 4 ml phosphate-buffered saline, n ¼ 10) (from bregma, AP: À2 mm, ML: 1.5 mm V (from dura): 2 mm). Three days after glioma cell implantations, mice were imaged for Fluc activity before their distribution into two experimental groups. hNSCexpressing aaTSP-1 or GFP-Rluc only were harvested and implanted stereotactically (0.5 Â 10 6 in 5 ul phosphate-buffered saline) (from bregma, AP: À2 mm, ML: 1.0 mm V (from dura): 2 mm, n ¼ 5 in each case). Mice were imaged sequentially for Fluc and Rluc activity starting day 3 as described earlier (Sasportas et al., 2009 ). On day 16, mice were killed and glioma tumors were resected for histopathological analysis. For intravital microscopy (described in detail in Supplementary methods section), a small circular portion of the cortical surface was exposed and a mix of tdTomato glioma cells (200 000 cells per mouse) and hNSC either expressing aaTSP-1 or GFP-Rluc (200 000 cells per mouse) glioma cells were implanted stereotactically (from bregma, AP: À2 mm, ML: 1.5 mm V (from dura): 2 mm) (n ¼ 3 in each case). Mice were injected intravenously with Angiosense-750 (Visen Medical; 20 nmol per mouse) and intravital microscopy was performed.
Tissue processing and immunohistochemisty
Immediately following the last imaging session, mice were perfused by pumping ice-cold 4% PFA directly into the heart for 5 min and prepared for immunohistochemistry, the details of which are described in the Supplementary methods section.
Statistical analysis
Data were analyzed by Student's t-test when comparing two groups and by analysis of variance, followed by Dunnett's post test when comparing greater than two groups. Data were expressed as mean ± s.e.m. and differences were considered significant at Po0.05. Survival times of the mouse groups treated with hNSC-aaTSP-1 and hNSC-GFP-Rluc were compared using log-rank tests.
